Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Administration of Allogenic Red Blood Cells Loaded L-asparaginase in Cases of Relapse of Acute Lymphoblastic Leukaemia (GRASPALL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00723346
Recruitment Status : Completed
First Posted : July 28, 2008
Last Update Posted : January 11, 2012
Centre Leon Berard
Information provided by (Responsible Party):
ERYtech Pharma

Brief Summary:

Primary objective :

  • To explore the relation between 3 doses of GRASPA and duration of asparagine depletion (< 2µmol/l)

Secondary objective :

  • Pharmacokinetic / Pharmacodynamic parameters
  • toxicity
  • Study duration : 2 years
  • Study treatment : Red blood cells loaded with L asparaginase versus native L asparaginase
  • Associated treatments : COPRALL chemotherapy
  • Randomization : centralised randomisation on scratching list

Condition or disease Intervention/treatment Phase
Acute Lymphoblastic Leukemia Biological: GRASPA Drug: native L asparaginase Phase 1 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 25 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Administration of Allogenic of Red Blood Cells Loaded L Asparaginase in Acute Lymphoblastic Leukemia Relapse.
Study Start Date : January 2006
Actual Primary Completion Date : August 2008
Actual Study Completion Date : March 2009

Arm Intervention/treatment
Experimental: 1 Biological: GRASPA
50 UI/Kg

Experimental: 2 Biological: GRASPA
100 UI/Kg

Experimental: 3 Biological: GRASPA
150 UI/Kg

Active Comparator: 4 Drug: native L asparaginase
10000UI/m2, 14 infusions during 4 chemotherapy cycle

Primary Outcome Measures :
  1. Duration of plasmatic asparagin depletion (< 2µmol/l) [ Time Frame: PK points ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   1 Year to 55 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject between 1 and 55 year old
  • Subject with acute lymphoblastic leukaemia or lymphoblastic lymphoma (excluded burkitt lymphoma) who have relapsed after first remission (medullary or SNC relapse)
  • Or patient who still refractory to first line chemotherapy for an ALL
  • Patient who gave written informed consent (2 parents for children)

Exclusion Criteria:

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00723346

Layout table for location information
Hopital Debrousse
Lyon, France, 69005
Sponsors and Collaborators
ERYtech Pharma
Centre Leon Berard
Layout table for investigator information
Principal Investigator: Yves Bertrand, MD PhD Hospices Civils de Lyon
Layout table for additonal information
Responsible Party: ERYtech Pharma Identifier: NCT00723346    
Other Study ID Numbers: GRASPALL 2005-01
First Posted: July 28, 2008    Key Record Dates
Last Update Posted: January 11, 2012
Last Verified: January 2012
Keywords provided by ERYtech Pharma:
Lymphoma lymphoblastic
Additional relevant MeSH terms:
Layout table for MeSH terms
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Leukemia, Lymphoid
Neoplasms by Histologic Type
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Disease Attributes
Pathologic Processes
Antineoplastic Agents